BioSpace News Archive

Coherus BioSciences, Inc., announced the Company has entered into a licensing agreement with Innovent Biologics, Co., Ltd.,, a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® in the United States and Canada.

Chiesi Farmaceutici S.p.A. and Apotex, Inc. announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.

Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced preliminary unaudited revenue results for the fourth quarter and full year 2019.

Healthpeak Properties, Inc. announced that it has executed a long-term lease with Janssen BioPharma, Inc., part of the Johnson & Johnson Family of Companies, for approximately 60% of Phase II at The Shore at Sierra Point.

Leading Israeli HMO Evaluates the Clinical Use of EarlySign’s Algorithm to Identify Patients at High Risk of Flu Complications

ICON plc, a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020.

Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results

A 17-year-old male patient with a severed extensor tendon of his thumb due to traumatic injury became the first outside of a clinical trial to undergo tendon repair with CoNextions Medical’s TR Tendon Repair device since the product’s recent approval in Chile, the first country to approve the device.

Company to Host R&D Symposium for Investors/Analysts on Tuesday January 14, 2020 in San Francisco, CA from 6:30 to 8:00 am (Pacific Time)